Progyny Inc. (PGNY)$24.88
Market Cap: 2.00 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Progyny Inc. (PGNY).
HEALTHCARE
HEALTHCARE PLANS
DCF ready
Valuation
9.9x
EV/FCF, 10.1% FCF yield
Quality
11.3%
ROIC, 14.9% FCF margin
Growth
30.2%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 2.7x current ratio
Superinvestors
2
Top: Robert Olstein (0.2%)
Strengths to research
- Revenue compounded at 30.2% over five years.
- Free cash flow compounded at 40.4% over five years.
- Free cash flow margin is healthy at 14.9%.
- Debt/equity looks manageable at 0.0x.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 9 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for PGNY.
Grade B
82
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| PGNY Target | Progyny Inc. | $2.0B | 38.3x | 9.9x | 11.3% | 30.2% | 14.9% | 23.6% | -1.2x | N/A |
| LIVN | LivaNova PLC | $2.0B | -16.6x | 9.9x | -15.4% | 8.2% | 12.5% | 67.7% | -1.1x | N/A |
| ENOV | Enovis Corp. | $2.0B | -1.2x | 161.2x | -42.5% | 14.9% | 0.9% | 59.8% | 5.7x | N/A |
| ACHC | Acadia Healthcare Co. | $2.1B | -1.9x | -10.2x | -24.8% | 9.7% | -13.3% | N/A | N/A | N/A |
| TVTX | Travere Therapeutics Inc. | $1.9B | -153.2x | 47.9x | -22.2% | 19.9% | 7.7% | N/A | N/A | N/A |
| QDEL | QuidelOrtho Corp. | $1.9B | -0.7x | -53.0x | -24.5% | 10.4% | -3.0% | N/A | N/A | N/A |
| NAMS | Newamsterdam Pharma Co Nv | $2.2B | -20.6x | -11.7x | -29.7% | N/A | -657.8% | N/A | N/A | N/A |
| OGN | Organon & Co. | $2.3B | 18.7x | 19.2x | 2.0% | -1.0% | 8.7% | 53.3% | N/A | N/A |
| EWTX | Edgewise Therapeutics Inc. | $1.7B | -20.1x | -11.6x | -0.0% | N/A | N/A | N/A | N/A | N/A |
Financial Charts
No financial data available for PGNY (annual).
2 superinvestors own PGNY
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| First Eagle Investment Management First Eagle Investment Management | 196,612 | $3M | 0.01% | 0.0% |
| Robert Olstein Olstein Capital Management | 56,000 | $951,000 | 0.21% | 0.0% |